Summary by Moomoo AI
On February 1, 2024, Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced the successful closing of its public offering, which was previously disclosed. The offering included 4,375,000 shares of common stock or pre-funded warrants and two classes of warrants to purchase up to 8,750,000 shares of common stock. The offering was priced at $2.06 per share and associated Public Warrants, and $2.059 per pre-funded warrant and associated Public Warrants. The gross proceeds from the offering amounted to approximately $9.0 million, before deducting placement agent fees and other offering expenses. Panbela intends to use the net proceeds for clinical development of its product candidates, working capital, business development, and other corporate purposes, which may include debt repayment. Following the offering, Panbela had 3,481,298 shares of common...Show More